A 3-D bismuth–organic framework containing 1-D cationic inorganic [Bi2O2]2+ chains

Tran, Dat T.; Chu, Deryn; Oliver, Allen G.; Oliver, Scott R. J.

doi:10.1016/j.inoche.2009.08.030

Cited by 29 publications

(15 citation statements)

References 26 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Along the centre of the rods, O 2− anions bridge alternatingly three (µ 3 ) and four (µ 4 ) Bi 3+ cations. The IBU of BSS is very similar but not identical to those found in a number of previously reported bismuth-based coordination polymers 33 , 38 – 41 . There are two types of salicylate anions (Hsal − ) in the BSS structure.…”

Section: Resultssupporting

confidence: 78%

Structure of the active pharmaceutical ingredient bismuth subsalicylate

et al. 2022

View full text Add to dashboard Cite

Structure determination of pharmaceutical compounds is invaluable for drug development but remains challenging for those that form as small crystals with defects. Bismuth subsalicylate, among the most commercially significant bismuth compounds, is an active ingredient in over-the-counter medications such as Pepto-Bismol, used to treat dyspepsia and H. pylori infections. Despite its century-long history, the structure of bismuth subsalicylate is still under debate. Here we show that advanced electron microscopy techniques, namely three-dimensional electron diffraction and scanning transmission electron microscopy, can give insight into the structure of active pharmaceutical ingredients that are difficult to characterize using conventional methods due to their small size or intricate structural features. Hierarchical clustering analysis of three-dimensional electron diffraction data from ordered crystals of bismuth subsalicylate revealed a layered structure. A detailed investigation using high-resolution scanning transmission electron microscopy showed variations in the stacking of layers, the presence of which has likely hindered structure solution by other means. Together, these modern electron crystallography techniques provide a toolbox for structure determination of active pharmaceutical ingredients and drug discovery, demonstrated by this study of bismuth subsalicylate.

show abstract

Section: Resultssupporting

confidence: 78%

Structure of the active pharmaceutical ingredient bismuth subsalicylate

et al. 2022

View full text Add to dashboard Cite

show abstract

“…26 reported bismuth based MOFs (we were able to establish < 20). [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] Notably, zur Loye and coworkers have reported a number of Bi coordination polymers and their fluorescence properties using pyridine dicarboxylate as ligand. [44][45][46][47][48] Stock, Cheetham and co-workers have also reported a small variety of interesting Bi-MOFs.…”

mentioning

confidence: 99%

High-Performance Blue-Excitable Yellow Phosphor Obtained from an Activated Solvochromic Bismuth-Fluorophore Metal–Organic Framework

Deibert

Velasco

Liu

et al. 2016

Crystal Growth & Design

View full text Add to dashboard Cite

We report the synthesis, structure, and photoluminescence properties of a new bismuth based luminescent metal−organic framework (LMOF). The framework is comprised of a 9-coordinated Bi 3+ building unit and 4′, 4‴, 4⁗′, 4⁗‴-(ethene-1,1,2,2-tetrayl)tetrakis([1,1′-biphenyl]-4carboxylic acid) (H 4 tcbpe) organic linker, which has strong yellow aggregation induced emission (AIE). The structure can be viewed as two interpenetrated 4,4-anionic nets that are stabilized by K + ions forming one-dimensional helical inorganic chains by connecting bismuth nodes through shared oxygen bonds. The as-made LMOF has a bluish emission centered at 459 nm with an internal quantum yield of 57% when excited at 360 nm. The emission properties of the LMOF were found to be highly solvochromic with respect to DMF. Upon partial solvent removal, the framework undergoes significant red-shifting to a greenish emission centered at 500 nm. Complete removal of DMF results in additional red-shifting fluorescence coupled with structural changes. The resulting material has strong blue-excitable (455 nm) yellow emission centered at 553 nm, with a quantum yield of 74%, which is maintained after heating in air for 5 days at 90 °C. This is the second highest quantum yield value for blue-excited yellow emission among all reported LMOFs.

show abstract

“…The crystal structure contains one‐dimensional cationic inorganic Bi 2 O 2 + layers . This self‐assembly mode also can be seen in the MOF bismuth 3,5‐pyridinedicarboxylate . Additionally, they can be used as composite photocatalysts for pollutant removal under visible light irradiation .…”

Section: Introductionmentioning

confidence: 93%

Synthesis of halide anion‐doped bismuth terephthalate hybrids for organic pollutant removal

Zhao

Xiong

Chen

et al. 2016

Applied Organom Chemis

View full text Add to dashboard Cite

Halide anion-doped bismuth terephthalate hybrids were synthesized using a facile solvothermal method. Four series of hybrids doped with halide anions X À (F À , Cl À , Br À and I À ) were produced by varying the molar ratios (n) of X À relative to Bi (NO 3 ) 3 (n = 0.25, 0.5, 0.75 and 1) in dimethylformamide solution. The results indicated that 0.25 equiv. of different halide anion-doped bismuth terephthalate hybrids, especially BiBDC-Cl(0.25) and BiBDC-Br(0.25), exhibited excellent photocatalytic activity under visible light and UV light irradiation. They also exhibited excellent adsorption performance for Rhodamine B which could be attributed to high surface areas and negative charge on the surface of the catalysts. Moreover, the degradation of Rhodamine B under visible light irradiation is a photosensitization process andÀ is the most important active species. The halide anion-doped bismuth terephthalate hybrids are promising photocatalysts for removal of organic pollutants.

show abstract

A 3-D bismuth–organic framework containing 1-D cationic inorganic [Bi2O2]2+ chains

Cited by 29 publications

References 26 publications

Structure of the active pharmaceutical ingredient bismuth subsalicylate

Structure of the active pharmaceutical ingredient bismuth subsalicylate

High-Performance Blue-Excitable Yellow Phosphor Obtained from an Activated Solvochromic Bismuth-Fluorophore Metal–Organic Framework

Synthesis of halide anion‐doped bismuth terephthalate hybrids for organic pollutant removal

Contact Info

Product

Resources

About